Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$2.8MCash on Hand
0.4mo Cash Runway
Follow ANVS by emailGet an email when ANVS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ANVS, unsubscribe in one click. Privacy
📣 What ANVS Says Is Next
by January · “The Company plans to present the 6-month data at the AD/PD 2027 conference in Barcelona. · OLE-PD: Enrollment of new patients for the OLE-PD study is projected to be completed by January 29, 2027.”
Company press release, Nov 13, 2026 · SEC filing
in March 2027 · “Upcoming milestones · DUET-AD: Annovis expects last patient, last visit of the 6-month treatment period on December 31, 2026, and database lock on February 8, 2027, with topline results in March 2027.”
Company press release, Nov 13, 2026 · SEC filing
fourth quarter of 2026 · “The disease-modifying data readout is anticipated 18 months after the last patient is dosed. · PD OLE study : Annovis expects to complete enrollment for the PD OLE study in the fourth quarter of 2026. · NDA pathway : Based on the Phase 3 AD study outcomes, Annovis plans to engage with the FDA regarding a regulatory NDA submission for buntanetap as a symptomatic treatment for AD in early 2027 and as a disease-modifying treatment in early 2028.”
Company press release, May 15, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 13, 2026 ·
Earnings Reported Q3 2026 results: cash of $2.8 million as of September 30, 2026, net loss of $0.22 per share, and R&D expenses of $15.8 million. The company closed a $21.0 million public offering on November 6, 2026, and expects DUET-AD topline results in March 2027. Form 8-K · SEC filing · Press release
Nov 5, 2026 ·
Financing Annovis Bio is offering 19,000,000 shares of common stock at $1.00 per share, each with a warrant for one share, plus pre-funded warrants for up to 2,000,000 shares, for gross proceeds of about $21.0 million before fees. A director is buying 5,000,000 shares for about $5.0 million. Form 424B5 · SEC filing
Nov 5, 2026 ·
Financing Annovis priced a public offering of 19,000,000 shares and 2,000,000 pre-funded warrants with accompanying warrants for 21,000,000 shares at $1.00 per share, for gross proceeds of about $21.0 million. A director is buying $5.0 million of the offering. Closing is expected November 6, 2026. Form 8-K · SEC filing · Press release
Nov 4, 2026 ·
Shareholder vote Stockholders approved increasing authorized common stock from 70,000,000 to 140,000,000 shares, with 24,084,197 votes for (85.61% of votes cast). Stockholders also ratified an amendment increasing shares under the 2019 Equity Incentive Plan, with 12,205,047 votes for (83.76% of votes cast). Form 8-K · SEC filing
Nov 4, 2026 ·
Earnings Annovis Bio estimates cash and cash equivalents of approximately $2.8 million as of September 30, 2026, based on preliminary unaudited figures before quarterly closing. The company's interim financial statements are not yet complete and the estimates may change. Form 8-K · SEC filing
Nov 4, 2026 ·
Financing Annovis Bio proposes a registered offering of common stock with accompanying five-year warrants, plus pre-funded warrants for certain investors. Canaccord Genuity is underwriter. Amounts are blank in this preliminary prospectus. Last reported NYSE price was $1.09 on November 3, 2026. Form 424B5 · SEC filing
Oct 30, 2026 ·
Listing NYSE notified Annovis that it fell below the $50 million minimum for both average market capitalization and stockholders' equity. The 30-day average market cap was about $48.4 million and the stockholders' deficit was about $(4.3) million at June 30, 2026. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2027 · Phase 3 · Active Trial · A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD Registry primary completion date, not a results date
Sep 2029 · Phase 2/3 · Recruiting · A Study of Buntanetap in Participants With PD Registry primary completion date, not a results date
Feb 2030 · Phase 2/3 · Upcoming Trial · An Open-label Long-term Safety Study of Buntanetap in Participants With AD Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
ANVS holds $2.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $19M/quarter from operations,
an estimated runway of 0.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:90 · High
Cash runway 0 months +40
ATM program on file since Feb 2025 +15
Shelf registration (S-3, Feb 2024) +10
Going-concern doubt in the latest 10-Q +15The Company expects that its existing balance of cash and cash equivalents, as of September 30, 2026, is not sufficient to fund operations for the period through one year after the date of this filing and therefore, Management has concluded that substantial doubt exists about the Company’s ability to continue as a…10-Q, Nov 2026
Share count +134% in a year +20
Raised after last reported balance sheet (Nov 2026) -10
Share count 62,022,520 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full ANVS picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ANVS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.